Celgene's most recent trend suggests a bullish bias. One trading opportunity on Celgene is a Bull Put Spread using a strike $142.00 short put and a strike $137.00 long put offers a potential 26.58% return on risk over the next 27 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $142.00 by expiration. The full premium credit of $1.05 would be kept by the premium seller. The risk of $3.95 would be incurred if the stock dropped below the $137.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Celgene is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Celgene is bullish.
The RSI indicator is above 80 which suggests that the stock is in overbought territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Celgene
See what the IHS Markit Score report has to say about Celgene Corp.
Thu, 21 Sep 2017 12:03:29 +0000
Celgene Corp NASDAQ/NGS:CELG
Top Research Reports for Northrop Grumman, BNY Mellon & Celgene
Wed, 20 Sep 2017 20:47:08 +0000
Top Research Reports for Northrop Grumman, BNY Mellon & Celgene
3 Stocks That Put Coca-Cola's Returns to Shame
Wed, 20 Sep 2017 12:25:00 +0000
Coca-Cola has been a great investment over the decades. But these stocks are leaving the soda giant in the dust.
These 3 Biotech Stocks Just Hit 52-Week Highs: Are They Buys?
Tue, 19 Sep 2017 11:31:00 +0000
Will the good times keep rolling for Abeona Therapeutics, BeiGene, and Vanda Pharmaceuticals?
Yes, Juno Therapeutics (JUNO) Just Became a Great CAR-T Trade
Tue, 19 Sep 2017 11:09:37 +0000
Juno Therapeutics Inc (NASDAQ:JUNO) is poised to benefit from a rising acquisition trend. Three weeks ago when Gilead Sciences, Inc. (NASDAQ:GILD) announced it would be acquiring smaller rival biopharma name Kite Pharma Inc (NASDAQ:KITE), traders clearly took notice. If Gilead wanted Kite for its CAR-T cancer therapy and Novartis AG (ADR) (NYSE:NVS) recently won the first-ever FDA approval for its CAR-T based oncology drug, there had to be something to it.
Related Posts
Also on Market Tamer…
Follow Us on Facebook